Intellectual Disability, Psychosis
Conditions
Brief summary
This clinical trial will prove whether a large number of people with intellectual disability and treatment-resistant psychosis could benefit from the use of clozapine. Benefit will mean a measurable significant improvement in subjects' clinical response and quality of life.
Detailed description
Randomized, open-label, multicenter phase II clinical trial that seeks to evaluate the safety and efficacy of clozapine versus standard clinical treatment in patients between the ages of 16 and 55 with intellectual disability and treatment-resistant psychosis. Clozapine is the most effective antipsychotic for patients with non-affective psychosis who do not respond to other first and second generation antipsychotic treatments. In addition, it has been shown to be very effective in another series of clinical situations such as hostility and aggressiveness, polydipsia and in behavioral disorders and psychosis, frequent situations in people with intellectual disabilities. The primary objective is to assess the efficacy and safety of clozapine versus standard clinical practice treatment in patients with intellectual disability and resistant psychotic disorder, as measured by change in Clinical Global Impression: Clinical Global Impression-Schizophrenia scale (ICG-SCH) global score over trial visits. The study determines to reach a sample size of 114 patients distributed among the 25 active centers. Randomization is 1:1 and consists of 6 visits to the center spread over 12 months. At each visit, the patient will undergo a physical examination and sample collection, along with a clinical and cognitive evaluation using the scales provided in accordance with the clinical guidelines. In addition, if the patient falls into the experimental arm (Clozapine), it is necessary to collect a blood sample weekly during the first 18 weeks and biweekly until completing the 12 months of the study, so that the medical team has special control in the analytical parameters.
Interventions
DRUGClozapine
Start treatment with 12.5 mg every 12 hours with the recommendation to increase dosage by 25-50 mg/day provided it is well tolerated up to a level of 300-450 mg/day at the end of the second week
DRUGhaloperidol, pimozide, olanzapine, risperidone, amisulpride
Treatment as usual using first-generation or second-generation antipsychotics
Sponsors
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Subjects aged between 16 and 55 years * Diagnosis of intellectual disability according to the Diagnostic and Statistical Manual of Mental Disorders Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (confirmed by a Intelligence Quotient (IQ) Score between 35 and 70 in the Kaufman test) * Diagnosis of psychosis according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (confirmed by clinical interview). * Treatment Resistant to antipsychotic drugs except clozapine. * Behavioural disturbances and self-injurious behaviour over the last 6 months. * Written informed consent of patients or legal representative. * Negative pregnancy test (if apply)
Exclusion criteria
* Leukocytes \< 3500/mm3 and neutrophils \< 2000/mm3. * Hypersensitivity to clozapine or excipients. * Myeloproliferative disorders * Uncontrolled epilepsy in the last 2 years. * Paralytic ileus in the last 3 months. * Diagnosis of an autism spectrum disorder * Pregnancy and breastfeeding * Any diseases with clozapine contraindicated. * Any uncontrolled serious condition * Need of treatment with more than one antipsychotic drug or electroconvulsive therapy * Treatment with quinolones, drugs that cause agranulocytosis or drugs that affect the cytochrome P-450 enzymes. * Risk of suicide based on the Columbia-Suicide Severity Rating Scale
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical improvement based on Clinical Global Impression-Schizophrenia (CGI-SCH) scale score. | Baseline and 12 Months | Overall Severity of Illness as measured by change from baseline to last study visit score Minimum value = 1 Normal, not ill Maximum value = 7 Among the most severely ill |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical improvement based on Positive and Negative Syndrome Scale (PANSS) | Baseline and 12 Months | Clinical improvement as measured by change from baseline to last study visit score Subjects rated from 1 to 7 on 30 different symptoms (items). Positive scale 7 Items. minimum score = 7, maximum score = 49 Negative scale 7 Items. minimum score = 7, maximum score = 49 General Psychopathology scale 16 Items. minimum score = 16, maximum score = 112 PANSS Total score minimum = 30, maximum = 210 |
| Clinical improvement based on Scale for the Assessment of Negative Symptoms (SANS) | Baseline and 12 Months | Clinical improvement as measured by change from baseline to last study visit score. SANS is split into 5 domains, and within each domain separate symptoms are rated through a 6-point scale from 0 (absent) to 5 (severe). SANS Total score minimum = 0, maximum = 125 |
| Quality of Life Improvement based on the 5 levels Quality of Life 5 dimensional (5D) 5 levels (5L) questionnaire (Euro-QoL 5D-5L scale) | Baseline and 12 Months | Generic health status improvement measured by change from baseline to last study visit scores |
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | Up to 28 days after the last investigational medicinal product administration | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
Countries
Spain
Outcome results
None listed